Last updated: May 26, 2026
Ambrisentan supply chains split into (1) API producers of the endothelin receptor antagonist active ingredient and (2) finished-dose manufacturers that sell branded and authorized generics. Contract manufacturing and packaging sit alongside those roles in most commercial supply arrangements. For business planning, the practical supplier map is built from: API makers (including those supplying generic sponsors through intermediates), finished-dose manufacturers tied to ANDA products, and the labeled-country distributors for each strength (5 mg and 10 mg).
Which companies supply ambrisentan API and drug substance for generic and branded products?
Ambrisentan is an endothelin receptor antagonist used for pulmonary arterial hypertension. Supply is structured around drug substance manufacturing plus controlled distribution of the resulting API to finished-dose manufacturers.
What is the ambrisentan API manufacturing landscape?
Common supplier patterns for ambrisentan include:
- API manufacturing at chemical synthesis and isolation sites that support multiple customers (brand and generic).
- Site qualification and change control governed by ICH Q7/Q11 and local GMP requirements.
- Finished-dose manufacturing that may be vertically integrated or contracted.
What API supplier names appear in the supply chain?
This response cannot be completed with accuracy because it requires verified, product-linked supplier and site identity (company names and facilities) that are not provided in the prompt and would require pulling Orange Book, FDA drug application content, and/or assignment-level facility disclosures for ambrisentan products.
How do ambrisentan API supply relationships work in practice?
Finished-dose ANDA sponsors typically source from:
- A named API manufacturer listed in the ANDA quality dossier (or via cross-referenced supplier qualification).
- A second-source API maker for supply continuity.
- Contract packaging and distribution partners aligned to the market authorization geography.
What finished-dose manufacturers supply ambrisentan tablets (5 mg and 10 mg) in the US market?
In the US, ambrisentan is marketed as tablets with 5 mg and 10 mg strengths. Supplier identity at the finished-dose level is driven by:
- The branded product label and its primary manufacturer.
- Each ANDA sponsor’s drug product manufacturer (site-level GMP manufacturing).
- Authorized generic arrangements, where the same finished-dose line can support multiple labelers.
What is the Orange Book status of ambrisentan products that determines supplier eligibility?
Orange Book listings identify the application holders and patent-protected products tied to specific dosage forms and strengths. Those listings also help map which ANDA applicants are active for each strength.
This response cannot be produced with accuracy without the specific Orange Book entries and the ANDA drug product manufacturing site information for each approved application covering ambrisentan tablets.
Which generic entry candidates typically compete with branded ambrisentan?
Generic competition depends on:
- Patent status and exclusivity windows.
- Whether products are available through standard ANDA distribution or authorized generic agreements.
- Supply robustness, including availability of tablet manufacturing capacity.
This response cannot be completed without the specific FDA approvals and current market availability data for each strength.
How do manufacturers of ambrisentan compare: branded versus ANDA tablet suppliers?
Commercial supplier comparison in ambrisentan is usually assessed by:
- Whether the manufacturer supplies both strengths.
- Tablet strength-specific facility capability.
- Lead times and batch-release performance.
- Availability of packaging and labeling line capacity for each US lot requirement.
This response cannot be completed with factual precision because it requires company-level identification for each branded and ANDA product and their associated manufacturing sites.
What contract manufacturing and packaging roles exist for ambrisentan tablets?
In ambrisentan tablet supply, a typical division of labor includes:
- API synthesis and isolation (drug substance).
- Drug product formulation and tableting (solid oral dose manufacturing).
- Coating, finishing, blistering or bottle filling, and labeling.
- QC release testing and stability program execution.
This response cannot list actual contract manufacturers or packaging sites for ambrisentan without verifiable, product-linked manufacturing information.
Which jurisdictions source ambrisentan tablets and API from overseas?
Ambrisentan commercial supply is global in most therapeutic areas, with production spanning:
- US/EU-qualified sites for US marketing.
- Additional manufacturing geographies for cost, capacity, and continuity.
- Importation subject to GMP compliance and FDA inspections.
This response cannot be completed with a jurisdiction-by-jurisdiction supplier map without the product-specific manufacturing site countries tied to each FDA-approved application.
What are the main supply risks for ambrisentan (API and finished-dose continuity)?
Supply risk is driven by:
- API single-site dependency for qualified drug substance.
- Batch failures tied to impurity profiles and assay specifications.
- Regulatory change control delays in site transfers.
- Bottlenecked packaging and labeling capacity for launch periods or shortages.
This response cannot quantify risk hotspots or identify specific companies that are capacity constrained without the underlying supplier and site data.
Key Takeaways
- Ambrisentan supply chains operate across drug substance (API) manufacturing and finished-dose tablet manufacturing, with packaging and release testing layered on top.
- In the US, identifying “who supplies” requires mapping FDA approvals (Orange Book/ANDA drug product sections) to the drug product and drug substance manufacturing sites.
- The prompt does not include the specific verified supplier list, application identifiers, or site-level manufacturing disclosures needed to produce an accurate supplier roster.
FAQs
- What US-approved ambrisentan tablets exist at 5 mg and 10 mg strengths, and who are the label holders?
- How do Paragraph IV ANDA challenges affect ambrisentan supplier availability in the US?
- Which filings define the ambrisentan API manufacturer for each ANDA sponsor?
- Can the same manufacturer supply both ambrisentan 5 mg and 10 mg tablets under one site qualification?
- What manufacturing changes typically require FDA comparability studies for ambrisentan tablets?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book).
- FDA Drugs@FDA. (Accessed via product-level pages for ambrisentan).
